Announced Fri, 6 Nov, 2026 · 18:02 IST
Q2 FY27 recovery strengthens, with a stronger second half expected
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Q2 FY27 revenue was INR 4,766 million, down 14.2% year on year but up 12.9% sequentially. Adjusted EBITDA was INR 459 million, with margin recovering to 9.6% from 2.2% in Q1, and adjusted profit after tax reached INR 74 million. Pharma contract manufacturing and specialty chemicals declined, while API+ grew 6.2% and Sapala 33.6%. Management expects a stronger second half on better order visibility.
Likely market impact
The sequential recovery and stronger second-half outlook may support sentiment, but falling revenue, first-half losses and margin pressure keep near-term risks elevated.